ArticleScientific reports2022

CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.

Jia-Shiong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.